Press Release

September 16, 2024

Abata Therapeutics Appoints Joanne Beck, Ph.D., as Chief Technical Officer

August 22, 2024

Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive Multiple Sclerosis

August 15, 2024

Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement of its Treg Cell Therapy Pipeline into Clinical Development

Abata Therapeutics Announces FDA Clearance of Investigational New Drug Application for Clinical Evaluation of ABA-101 in Progressive Multiple Sclerosis

August 28, 2023

Abata Therapeutics to Present and Participate in Upcoming Investor and Industry Events

August 24, 2023

Abata Therapeutics Announces Second Development Candidate, ABA-201, a Novel Treg Cell Therapy for the Treatment of Type 1 Diabetes

Abata Therapeutics to Present at Upcoming Investor and Industry Events in June

Abata Therapeutics Announces the Appointment of Leonard Dragone, M.D., Ph.D., as Chief Medical Officer

December 14, 2022

Abata Therapeutics Announces First Development Candidate, ABA-101, a Novel Treg Cell Therapy for the Treatment of Progressive Multiple Sclerosis